1. Home
  2. PHAR vs ESQ Comparison

PHAR vs ESQ Comparison

Compare PHAR & ESQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

HOLD

Current Price

$16.62

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo Esquire Financial Holdings Inc.

ESQ

Esquire Financial Holdings Inc.

HOLD

Current Price

$107.01

Market Cap

858.2M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHAR
ESQ
Founded
1988
2006
Country
Netherlands
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Commercial Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
858.2M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
PHAR
ESQ
Price
$16.62
$107.01
Analyst Decision
Strong Buy
Hold
Analyst Count
2
3
Target Price
$38.00
$113.00
AVG Volume (30 Days)
23.0K
68.8K
Earning Date
11-06-2025
01-22-2026
Dividend Yield
N/A
0.66%
EPS Growth
N/A
14.70
EPS
0.00
5.68
Revenue
$362,274,000.00
$131,743,000.00
Revenue This Year
$24.80
N/A
Revenue Next Year
$6.84
$18.55
P/E Ratio
$2,921.20
$19.11
Revenue Growth
26.78
13.37
52 Week Low
$7.50
$68.90
52 Week High
$18.12
$108.77

Technical Indicators

Market Signals
Indicator
PHAR
ESQ
Relative Strength Index (RSI) 51.06 61.43
Support Level $16.23 $105.38
Resistance Level $17.00 $108.77
Average True Range (ATR) 0.75 2.81
MACD -0.16 0.21
Stochastic Oscillator 36.44 79.46

Price Performance

Historical Comparison
PHAR
ESQ

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

About ESQ Esquire Financial Holdings Inc.

Esquire Financial Holdings Inc is a financial holding company. Through its subsidiary, the company operates as a full-service commercial bank dedicated to serving the financial needs of the legal industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The Bank offers tailored products and solutions to the legal community and their clients as well as dynamic and flexible payment processing solutions to small business owners. Banking products offered for businesses and consumers include checking, savings, money market, and time deposits; a wide range of commercial and consumer loans, as well as customary banking services. In addition, it operates a payment processing platform through third-party independent sales organizations.

Share on Social Networks: